Cáncer de riñón en adulto (carcinoma de células renales)

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: guía detallada del cáncer de riñón

Abreu SC, Finelli A, Gill IS. Management of localized renal cell carcinoma: minimally invasive nephron-sparing treatment options. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, eds. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:755-765.

American Cancer Society. Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society; 2013.

American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY. Springer; 2010:479-486.

Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008 Nov 1;113(9):2457-2463.

Choyke PL. Radiologic imaging of renal cell carcinoma: its role in diagnosis. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, eds. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:709-723.

Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):801-7.

Hawkins RE, Macdermott C, Shablak A, et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother. 2009 May;32(4):424-9.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.

Linehan WM, Schmidt LS. Molecular biology of kidney cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cáncer:
Principles and Practice of Oncology
. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1154-1160.

Linehan WM, Rini BI, Yang JC. Cancer of the kidney. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cáncer:
Principles and Practice of Oncology
. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1161-1182.

McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.

Mulders P, Hawkins R, Nathan P, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer. 2012 Mar;48(4):527-37. Epub 2012 Jan 28.

National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. V.2.2012. Accessed at: www.nccn.org on June 5, 2012.

Prenen H, Gil T, Awada A. New therapeutic developments in renal cell cancer. Critical Rev Oncol Hematol. 2009;69(1):56-63.

Pili R, Rodriguez R. Cancer of the kidney. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa. Elsevier: 2008:1613-1634.

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931-9. Epub 2011 Nov 4.

Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20;27(27):4462-8. Epub 2009 Aug 3.

Schwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009 Aug 1;15(15):4986-92.

Tannir NM, Wong YN, Kollmannsberger CK, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011 Dec;47(18):2706-14. Epub 2011 Nov 10.

Zisman A, Pantuck A, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559-4566.


Fecha de última actualización: 12/11/2012
Fecha de último cambio o revisión: 12/11/2012